GFAP and central nervous system cancer: Single-cell suspensions derived from fresh ex vivo GBM specimens demonstrated that FGL2 expression occurred primarily in the glioma subpopulation that expressed glia-specific marker GFAP (43.3 ± 14.3% of GFAP+ cells).